Lower recommended dose for etoricoxib

The recommended dose of Arcoxia (etoricoxib) has been reduced to 60mg daily for patients with rheumatoid arthritis or ankylosing spondylitis.

 Gastrointestinal complications (perforations, ulcers or bleeding), some fatal, have occurred in patients treated with etoricoxib. | SCIENCE PHOTO LIBRARY
Gastrointestinal complications (perforations, ulcers or bleeding), some fatal, have occurred in patients treated with etoricoxib. | SCIENCE PHOTO LIBRARY

Two randomised, double-blind, phase III trials have shown that a 60mg daily dose of etoricoxib is effective for the treatment of rheumatoid arthritis and ankylosing spondylitis, although some patients required an increased dose of 90mg daily.

As it is not possible to predict which patients may benefit from the higher dose, healthcare professionals should initiate treatment with a dose of 60mg once daily, with the option to increase to a maximum dose of 90mg once daily in patients with insufficient relief from symptoms.

As a selective COX-2 inhibitor, etoricoxib may be associated with an increased risk of cardiovascular and gastrointestinal events. These risks may increase with the dose and duration of exposure. The lowest effective daily dose should therefore be used and the need for treatment regularly reassessed.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...